Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Transaction History
Qube Research & Technologies LTD
- $82.3 Billion
- Q1 2025
A detailed history of Qube Research & Technologies LTD transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 118,808 shares of PLX stock, worth $191,280. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118,808
Previous 24,867
377.77%
Holding current value
$191,280
Previous $47,000
546.81%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.91 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.55 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.38 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$1.1 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$990,2860.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $80.1M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...